Description
ADCC-enhanced Atezolizumab is a non-fucosylated anti-CD274 therapeutic biobetter antibody.
Antibody Indication
Cancers, ovarian, gastric, non-small cell lung (NSCLC), metastatic, Solid tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD274 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Alternative Names
Programmed cell death 1 ligand 1; B7H1; B7-H1; PDL1; PD-L1; PDCD1L1; B7 homolog 1; B7 homologue 1
Cellular Localization
Plasma membrane, Endosome
Involvement in Disease
Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma.
Related Pathways
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Function
It plays a key role in inducing and maintaining immune tolerance to oneself. As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells. Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10). Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival. The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).
Post-translational modifications
1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Atezolizumab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD274. Atezolizumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, non-small cell lung (NSCLC), Solid tumors, bladder, urothelial.
Antibody Indication
Cancers, ovarian, gastric, non-small cell lung (NSCLC), metastatic, Solid tumors
